Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $18.8M | $24.1M | $28.7M | $34.1M | $37.3M | $41.7M |
| Revenue growth | — | 27.9% | 19.0% | 18.8% | 9.5% | 11.7% |
| Operating income | -$9.61M | -$25.2M | -$18.6M | -$22.7M | -$17.2M | -$11.3M |
| Operating margin | -51.0% | -104.6% | -64.8% | -66.6% | -46.1% | -27.2% |
| Net income | -$11.0M | -$37.7M | -$640K | -$20.1M | -$17.8M | -$10.5M |
| Net margin | -58.3% | -156.5% | -2.2% | -59.1% | -47.6% | -25.3% |
| EPS (diluted) | -$479.48 | -$4.28 | -$0.61 | -$13.02 | -$3.22 | -$1.04 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$12.4M | -$26.7M | -$16.2M | -$24.9M | -$10.3M | -$13.4M |
| Capital expenditures | — | — | $38.0K | $5.00K | $10.0K | $2.00K |
| Free cash flow | — | — | -$16.2M | -$24.9M | -$10.3M | -$13.4M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.08M | $24.5M | $17.2M | $1.34M | $5.91M | $6.39M |
| Total assets | $24.1M | $53.2M | $50.9M | $27.9M | $22.1M | $28.6M |
| Total liabilities | $18.3M | $41.9M | $27.0M | $23.1M | $17.7M | $18.1M |
| Shareholders' equity | $5.83M | $11.3M | $23.9M | $4.79M | $4.43M | $10.5M |
| Retained earnings | -$41.2M | -$78.9M | -$79.5M | -$99.7M | -$117M | -$128M |
| Shares (wtd avg diluted) | 8.00M | 8.81M | 1.06M | 1.55M | 5.52M | 10.2M |
Every figure is extracted from Biofrontera Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.